Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the use of intravitreal aflibercept (anti-VEGF therapy) in patients
with a type of macular degeneration known as vascularized pigment epithelial detachment.
Previous studies have shown a generally poor outcome in treating this difficult to treat form
of wet macular degeneration. More recently, multiple pilot studies have shown positive
benefits to using anti-VEGF therapy. This study will evaluate the safety and efficacy of
treating vascularize pigment epithelial detachment associated with wet macular degeneration
with intravitreal aflibercept injection.